Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 2 days ago

Definium Therapeutics, Inc.: Janus Henderson Group Ltd. discloses a stake of more than 5% (Schedule 13G)

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Janus Henderson Group Ltd. disclosed a stake exceeding 5% in Definium Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001274173-26-000279). The passive-investment disclosure signals the asset manager has crossed the key 5% beneficial-ownership threshold that triggers regulatory reporting requirements. The exact share count and percentage were not specified in the filing headline. Investors will watch for further 13G amendments or 13D filings that could indicate a shift from passive to activist intent.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Definium Therapeutics, Inc., Janus Henderson Group Ltd.